“We expect this momentum continues in the second half, and that's what gave us confidence here to raise our full year life science guide.”

In context

“ink it's also important to say that we see good traction on our recent commercial and growth initiatives. Abcam delivered their strongest quarter since acquisition, and they benefited from improved commercial execution, certainly. We're also taking some share here and making headway in other end markets to skew away a little bit from academic. We also think the new products are contributing to our growth in our life science instrument businesses, flow cytometry at Beckman, the novus V55 and 8600 at SCIEX. All those things are helpful. We're starting to see these little green shoots around the AI dynamic. We are seeing demand across our portfolio, including at Beckman, with increased automation for these lab-in-a-loop or autonomous science applications. We're starting to see that as well. We expect this momentum continues in the second half, and that's what gave us confidence here to raise our full year life science guide. Operator Thank you. We have now reached our allotted time for questions. I will now turn the call back over to Rachel Vatnsdal for final comments. Rachel Vatnsdal Great. Thank you everyone for joining us this morning. We'll be around the rest of the day and the rest of the week as well for follow-ups. Thank you. Operator Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.”